Menu Search
Equities

Kintor Pharmaceutical Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
9939:HKG.HZ

Kintor Pharmaceutical Ltd

Actions
  • Price (HKD)2.75
  • Today's Change-0.04 / -1.43%
  • Shares traded633.50k
  • 1 Year change+186.46%
  • Beta0.5197
Data delayed at least 15 minutes, as of Feb 16 2026 04:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Kintor Pharmaceutical Ltd is an investment holding company primarily engaged in the research and development of innovative medicine products. The Company's products are dedicated to addressing disease areas that have not met clinical needs, and its pipeline mainly covers indications of dermatology (such as androgenetic alopecia, acne vulgaris) and indications of tumors. The Company has two core drugs in the dermatology field, KX-826 and GT20029. The Company's other disease areas include metastatic castration-resistant prostate cancer (mCRPC), liver cancer, idiopathic pulmonary fibrosis, malignant blood diseases and various solid tumors.

  • Revenue in HKD (TTM)12.44m
  • Net income in HKD-189.22m
  • Incorporated2018
  • Employees136.00
  • Location
    Kintor Pharmaceutical LtdNo. 20 Songbei RoadSuzhou Industrial ParkSUZHOU 215123ChinaCHN
  • Phone+86 51 262639909
  • Websitehttps://www.kintor.com.cn/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.